Phio Pharmaceuticals Corp.
(NASDAQ : RXII)

( )
RXII PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.71%203.211.3%$436.19m
BIIBBiogen Inc.
0.73%227.721.3%$386.27m
GILDGilead Sciences, Inc.
0.08%65.350.9%$368.51m
CELGCelgene Corporation
0.02%100.971.3%$353.70m
ILMNIllumina, Inc.
-0.80%309.673.5%$257.96m
REGNRegeneron Pharmaceuticals, Inc.
-1.46%299.402.6%$220.44m
EXASExact Sciences Corporation
-2.17%97.5824.1%$205.36m
ALXNAlexion Pharmaceuticals, Inc.
-5.06%99.512.0%$180.57m
VRTXVertex Pharmaceuticals Incorporated
-0.03%176.091.9%$177.48m
AAgilent Technologies, Inc.
-0.65%75.261.6%$148.26m
SRPTSarepta Therapeutics, Inc.
-1.49%86.7414.6%$140.12m
BMRNBioMarin Pharmaceutical Inc.
-0.83%67.944.3%$95.23m
ALDRAlder Biopharmaceuticals, Inc.
-0.05%18.8710.2%$90.77m
SGENSeattle Genetics, Inc.
0.58%83.866.2%$87.50m
NKTRNektar Therapeutics
1.42%17.545.5%$85.01m

Company Profile

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that address unmet medical needs. Its clinical product candidate includes RXI-109, a RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.